Sentences with phrase «results at trial»

Results at trial are always uncertain.

The Maryland personal injury lawyers at Miller & Zois have achieved successful results at trial in hundreds of car accident cases in Maryland.

So what should a client or company do when they want to get great results at trial, but they only have the budget to pay a lawyer who is good but not great?

We have achieved successful results at trial in hundreds of car accident cases in Maryland.

Convince the court of this and that party is unlikely to obtain beneficial results at trial.

Even when a settlement is reached, the firm's attorneys gain a superior bargaining position through the strength of the evidence they have compiled and through their history of achieving excellent results at trial.

Reed concludes that as with other juror studies, it's difficult to arrive at definitive conclusions about trends because there are so many variables (which I realized in discussing another recent study concluding that English - speaking Hispanics get better results at trial).

«English Speakers Get Better Results at Trial Main Dredging Up Archives Causes Run on Company Stock»

We have achieved extremely favorable results at trial and by settlements for our clients in medical malpractice cases and cases involving birth injuries, such as delivery trauma and negligent prenatal care.

If we are not satisfied with the settlement offers, or if we know that we can get a better result at trial, we will not hesitate to take your case to court.

He's able to put the client at ease with his confident grasp of the subject material and he comes up with inventive suggestions for maximising the best result at trial.»

On reconsideration and after having spoken to a an expert or two, I've concluded that all the panel meant by para 787 is that (1) there were two valid choices that could be made on the evidence: guilty or not guilty; (2) the panel thought that the more probable result at any trial would be not guilty; and (3) in the circumstances, since the ONLY routes open to the panel in light of the miscarriage finding was a new trial or the entry of an acquittal and since a new trial was inappropriate etc in the circumstances the correct procedure was to enter the acquittal.

Regardless of the case's complexity or potential exposure, our goal remains the same — explore the most efficient, cost - containment solution available, but when necessary, fight relentlessly to achieve the best result at trial.

The first was that the trial judge had missed or ignored a number of key pieces of evidence which, if addressed, would have likely rendered a different result at trial.

Not exact matches

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

Even the glitteriest of gold - standard clinical trials, for instance, are often undone by a leaden follow - up study that has the nerve to arrive at a different result.

Until the clinical trial's results are released, there won't be enough evidence that taking the drug can improve your lifespan, at least in the eyes of the FDA.

... This means that there are multiple «active» token numbers for each customer at any given time,» Hursti said, adding that he recalls a tokenization trial for «black cards» for high net worth cardholders that resulted in each user having «thousands of active numbers issued to them at any given time.»

Actual results and the timing of events could differ materially from those anticipated in the forward - looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the uncertain timing of, and risks relating to, the executive search process; risks related to the potential failure of eptinezumab to demonstrate safety and efficacy in clinical testing; Alder's ability to conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sec.gov.

At trial, a federal jury in Manhattan in 2014 awarded the EMI companies nearly $ 48.1 million, a sum U.S. District Judge William Pauley in Manhattan later reduced, resulting in a $ 12.2 million judgment against Robertson.

While the asthma trial data is just one point, the study's results could go a long way in assuring scientists that information generated through the platform (at least for certain kinds of studies) is on point.

When Jedd Wolchok, a cancer doctor and immunologist leading a Yervoy trial at Memorial Sloan Kettering, examined a melanoma patient's scan 12 weeks after he'd received his course of treatment, the results were utterly disappointing — just like those of any other metastatic patient in the final throes of the disease: The tumors had gotten bigger, and there were more of them.

A randomized trial conducted by the Jameel Poverty Action Lab at MIT will be published this year, but preliminary results suggest Living Goods is significantly exceeding its target.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

A March 28, 2018, research note by JMP Securities analyst Michael King indicated that at the recent International Symposium on Amyloidosis in Japan, Alnylam Pharmaceuticals Inc. (ALNY: NASDAQ) reported multiple sets of results of clinical trials, separately evaluating its investigational RNA interference (RNAi) therapeutics patisiran and ALN - TTRsc02.

Torture and public trials resulted in burnings at the stake of poor and working - class women viewed as symbols of rebellion against the ruling church.

[Y] ou have been distressed by various trials, so that the proof of your faith, being more precious than gold which is perishable, even though tested by fire, may be found to result in praise and glory and honor at the revelation of Jesus Christ.

But if we are trying by persuasion to evoke a feeling in another person, (1) we can specify only roughly, not exactly, what we are aiming at and (2) we do not expect to get repeatable results; therefore, we do not speak of trial and error or experimenting in this context.

At least some of the politicians like our president made their accusations before the trial which just resulted in tainting the jury pool but was not yet finished.

In 2014, we shared an update on the results of the multilocation trials (MLTs) conducted in 2012 - 2013 that used the most advanced event of Golden Rice at that time, GR2R.

The decision to use VAR at the World Cup has not been an entirely popular one due to mixed results from a series of trials across the world.

The results of a recent randomized trial of CSRP showed that children who spent their prekindergarten year in a CSRP Head Start classroom had, at the end of the school year, substantially higher attention skills, greater impulse control, and better performance on executive - function tasks than did children in a control group.

Although not directly comparable, our findings are in broad agreement with those from routine data in Scotland that have indicated a positive association between Baby Friendly accreditation, but not certification, and breastfeeding at 1 week of age.17 Our findings reinforce those of Coutinho and colleagues who reported that high exclusive breastfeeding rates achieved in Brazilian hospitals implementing staff training with the course content of the Baby Friendly Hospital Initiative were short - lived and not sustained at home unless implemented in combination with post-natal home visits.35 Similarly in Italy, training of staff with an adapted version of the Baby Friendly course content resulted in high breastfeeding rates at discharge, with a rapid decrease in the days after leaving hospital.36 In contrast, a cluster randomized trial in Belarus (PROBIT) found an association between an intervention modelled on the Baby Friendly Initiative with an increased duration of breastfeeding37 an association also reported from an observational study in Germany.38 Mothers in Belarus stay in hospital post-partum for 6 — 7 days, and in Germany for 5 days, with post-natal support likely to be particularly important in countries where mothers stay in the hospital for a shorter time, with early discharge likely to limit the influence of a hospital - based intervention.

Although some SIDS experts and policy - makers endorse pacifier use recommendations that are similar to those of the AAP, 272,273 concerns about possible deleterious effects of pacifier use have prevented others from making a recommendation for pacifier use as a risk reduction strategy.274 Although several observational studies275, — , 277 have found a correlation between pacifiers and reduced breastfeeding duration, the results of well - designed randomized clinical trials indicated that pacifiers do not seem to cause shortened breastfeeding duration for term and preterm infants.278, 279 The authors of 1 study reported a small deleterious effect of early pacifier introduction (2 — 5 days after birth) on exclusive breastfeeding at 1 month of age and on overall breastfeeding duration (defined as any breastfeeding), but early pacifier use did not adversely affect exclusive breastfeeding duration.

At the end of the trial, the presidential results, which originally favoured the sitting President, John Dramani Mahama, were upheld by the Court.

Espada, who The Post disclosed yesterday may be indicted on criminal charges this summer as a result of Cuomo's probe, is expected to be put on trial at an administrative tribunal conducted by the Bronx Democratic organization.

There's been rumblings at the Capitol today that some Republicans would like to see Sen. Kevin Parker subjected the sort of trial - by - colleagues treatment received by former Sen. Hiram Monserrate that resulted in the ex-lawmaker's ouster from the chamber.

Observers will be watching to see how well he raises campaign cash, and also how he manages candidate recruitment — especially at a time when he has a number of aging members and two — including his predecessor, Dean Skelos; and his deputy majority leader, Tom Libous; facing federal corruption trials that could result in their abrupt ouster from office.

Two Syracuse businessmen charged with bribing Percoco found the results of his alleged actions on their behalf «amazing,» according to emails shown at the trial.

After the positive results from a random drug test, she was pulled from her security post at Gracie Mansion and remains on paid desk duty in Queens pending the outcome of the trial.

What's being revealed at trial of how the pay - to - play culture works in New York, which has resulted in a $ 30 million political war chest for the governor, is a case in point.

Solomon reminded him that results would not be evidence at her trial — but that he was welcome to use them for his purposes.

Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent, according to the results of one of the largest ever clinical trials for prostate cancer presented at the 2017 ASCO Annual Meeting in Chicago and published in the New England Journal of Medicine.

With the results of the trial in, health officials are discussing how to proceed with additional tests for ZMapp should more cases of Ebola arise, said Gary Disbrow, who helped lead Ebola response at the US government's Biomedical Advanced Research and Development Authority.

Results of the Phase II clinical trial were presented Feb. 23 at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

«Results of this trial are good news to patients with high blood levels of uric acid or those at risk for gout.

Inclisiran lowers low - density lipoprotein (LDL; «bad») cholesterol for up to one year in patients with high cardiovascular risk and elevated LDL cholesterol, according to late - breaking results from the ORION 1 trial presented today in a Hot Line LBCT Session at ESC Congress.

The researchers were never able to obtain the data from the original clinical trial sponsor and in the end had to painstakingly reconstruct the study results from the information collected at each individual study site.

Results from this early - stage clinical trial have not yet been published or reported at medical meetings.

This weekend at a MAPS - sponsored meeting here, Mithoefer reported similar results for nearly all of the trial's participants.